- Home
- NCNA vs DRMA Comparison
NCNA vs DRMA Comparison
Compare NCNA & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- DRMA
- Stock Information
- Founded
- NCNA 1997
- DRMA 2014
- Country
- NCNA United Kingdom
- DRMA United States
- Employees
- NCNA N/A
- DRMA N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- NCNA Health Care
- DRMA Health Care
- Exchange
- NCNA Nasdaq
- DRMA Nasdaq
- Market Cap
- NCNA 4.5M
- DRMA 4.5M
- IPO Year
- NCNA 2017
- DRMA 2021
- Fundamental
- Price
- NCNA $0.09
- DRMA $0.60
- Analyst Decision
- NCNA Buy
- DRMA Strong Buy
- Analyst Count
- NCNA 2
- DRMA 1
- Target Price
- NCNA $25.00
- DRMA $3.00
- AVG Volume (30 Days)
- NCNA 319.9M
- DRMA 94.5K
- Earning Date
- NCNA 08-14-2025
- DRMA 08-06-2025
- Dividend Yield
- NCNA N/A
- DRMA N/A
- EPS Growth
- NCNA N/A
- DRMA N/A
- EPS
- NCNA N/A
- DRMA N/A
- Revenue
- NCNA N/A
- DRMA N/A
- Revenue This Year
- NCNA N/A
- DRMA N/A
- Revenue Next Year
- NCNA N/A
- DRMA N/A
- P/E Ratio
- NCNA N/A
- DRMA N/A
- Revenue Growth
- NCNA N/A
- DRMA N/A
- 52 Week Low
- NCNA $0.03
- DRMA $0.57
- 52 Week High
- NCNA $10.79
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- NCNA 41.41
- DRMA 29.24
- Support Level
- NCNA $0.07
- DRMA $0.57
- Resistance Level
- NCNA $0.10
- DRMA $0.63
- Average True Range (ATR)
- NCNA 0.03
- DRMA 0.04
- MACD
- NCNA 0.01
- DRMA -0.01
- Stochastic Oscillator
- NCNA 25.70
- DRMA 11.55
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.